Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
OTX-DP · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Dexamethasone Punctum Plug | ACTIVE_COMPARATOR | Sustained and tapered release of dexamethasone from hydrogel punctum plug following insertion over 30 days |
| Placebo Vehicle Punctum Plug | PLACEBO_COMPARATOR | Placebo punctum plug insertion |
| Name | Type | Description |
|---|---|---|
| OTX-DP (Dexamethasone punctum plug) | DRUG | Sustained and tapered release of dexamethasone from hydrogel punctum plug |
| Placebo Vehicle Punctum Plug | DRUG | Hydrogel punctum plug without dexamethasone |
Inclusion Criteria: * Has provided written informed consent, approved by the appropriate institutional review board; and is able to comply with study requirements and visit schedule * Is greater than or equal to 21 years of age * Has a cataract and is expected to undergo clear corneal cataract surg...
OTX-DP is an investigational small molecule being developed for the treatment of ocular inflammation and pain, specifically for patients undergoing cataract surgery. It is administered to manage these postoperative symptoms in the eye.
OTX-DP is being developed by Ocular Therapeutix, Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol OCUL. The company is focused on ophthalmic therapies.
OTX-DP is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA. A Phase 2 study evaluating its safety and efficacy has been completed.
OTX-DP has one completed Phase 2 clinical trial, registered as NCT01666210. This study evaluated the safety and efficacy of OTX-DP for treating ocular inflammation and pain after cataract surgery in 60 participants in the United States.
OTX-DP is the investigational name for this drug candidate. No alternative names have been reported for this asset, and it is distinct from other products in Ocular Therapeutix's pipeline.